Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
103
result(s) for
"Mukherji, Deborah"
Sort by:
الغذاء والصحة في مرحلة الطفولة المبكرة
يقدم الكتاب عرضا للطعام والغذاء في سياق تاريخي وثقافي ونفسي والعادات الصحية التي يجب اتباعها في تناوله أثناء المراحل الأولى من الطفولة عن طريق تغطية الكثير من الموضوعات منها \"التغذية، تطوير السياسات، أوجه التباين الصحية، الطعام والثقافة والهوية، الطعام والعاطفة، إرشادات عامة لإتباع عادات صحية سليمة في تناول الطعام، الارتقاء بالعادات الصحية الواجب اتباعها خلال فترة الطفولة المبكرة، العمل متعدد التخصصات الذي يتعلق بتغذية الأطفال الصغار، كما يستهدف هذا الكتاب كافة المتعاملين مع الأطفال في سنواتهم الأولى.
BOOK
Secondary bile acids: an underrecognized cause of colon cancer
Bile acids were first proposed as carcinogens in 1939. Since then, accumulated evidence has linked exposure of cells of the gastrointestinal tract to repeated high physiologic levels of bile acids as an important risk factor for gastrointestinal cancers. High exposure to bile acids may occur in a number of settings, but most importantly, is prevalent among individuals who have a high dietary fat intake.
A rapid effect on cells of high bile acid exposure is the generation of reactive oxygen species and reactive nitrogen species, disruption of the cell membrane and mitochondria, induction of DNA damage, mutation and apoptosis, and development of reduced apoptosis capability upon chronic exposure. Here, we review the substantial evidence of the mechanism of secondary bile acids and their role in colon cancer.
Journal Article
مناهج البحث في مرحلة الطفولة المبكرة : دليل تمهيدي
يتناول كتاب \"مناهج البحث في مرحلة الطفولة المبكرة : دليل تمهيدي\" تأليف \"Penny Mukherji, Deborah Albon\" وقاما بترجمته \"د. لينا سعيد باشطح، د. هنادي فهد العثمان\" في حوالي (541) صفحة من القطع المتوسط موضوع (طرق البحث في مراحل الطفولة المبكرة)، يعتبر الكتاب من المراجع العلمية الشاملة والأكثر انتشارا في مجال دراسات الطفولة المبكرة. وتعد هذه النسخة المترجمة الأولى من نوعها باللغة العربية والتي تتكون من خمسة أجزاء رئيسة تتضمن تسعة عشر فصلا. يمتاز هذا الكتاب بتقديم مفاهيم البحث العلمي بأسلوب متدرج ومبسط حيث أجادت مؤلفتا الكتاب بتدعيم المفاهيم النظرية بأمثلة واقعية، دراسات حالة، لحظات تأمل، وبحوث تحت المجهر. ويركز هذا الكتاب بشكل خاص على مناهج البحث العلمي الملائم تطبيقها في دراسات مرحلة الطفولة المبكرة كما يسلط الضوء على طرق البحث الملائمة عند إشراك الأطفال في البحوث.
BOOK
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.
Journal Article
Cancer control in the United Arab Emirates
The United Arab Emirates (UAE) is confronting a growing cancer burden. Although the UAE continues to invest substantially in health care, increase in cancer cases places considerable health, economic, and societal strain on the country, and has been driven by the complexity of late-stage treatments, declines in workforce productivity, and broader effects of national economic output. The unique population demographic of the UAE, coupled with its health-care structure, requires a tailored approach to cancer control from screening to treatment. This Series paper evaluates the current state of cancer control in the UAE, identifying barriers and gaps in the current system and proposing actionable recommendations for improvement. A comprehensive national cancer control plan—supported by robust data, international partnerships, and strategic policy reforms—is urgently needed. Central initiatives include expanding early detection and screening efforts, improving access to multidisciplinary cancer centres, and adopting advanced diagnostic technologies. Additional priorities involve bolstering the oncology workforce, fostering public–private partnerships, elevating care quality, and harnessing digital health innovations. Public health education campaigns and equitable service distribution are also essential to improve the outcome of common malignancies, particularly breast, colorectal, and lung cancers. Guided by the UAE's Vision 2031 agenda, these measures aim to build a resilient oncology ecosystem that reduces mortality, optimises patient outcomes, and establishes a regional standard for equitable, high-quality cancer care.
Journal Article
A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)
Background
Intrahepatic cholangiocarcinoma (CCA) is amongst the most common primary liver tumors worldwide. CCA carries a bad prognosis prompting research to establish new treatment modalities other than surgery and the current chemotherapeutic regimens adopted. Hence, this trial explores a new therapeutic approach, to combine stereotactic body radiation therapy (SBRT) and immunotherapy (Nivolumab), and asses its clinical benefit and safety profile after induction chemotherapy in CCA.
Methodology
This is a Phase II open-label, single-arm, multicenter study that investigates Nivolumab (PD-1 inhibitor) treatment at Day 1 followed by SBRT (30 Gy in 3 to 5 fractions) at Day 8, then monthly Nivolumab in 40 patients with non-resectable locally advanced, metastatic or recurrent intrahepatic or extrahepatic CCA. Eligible patients were those above 18 years of age with a pathologically and radiologically confirmed diagnosis of non-resectable locally advanced or metastatic or recurrent intrahepatic or extrahepatic CCA, following 4 cycles of cisplatin-based chemotherapy with an estimated life expectancy of more than 3 months, among other criteria. The primary endpoint is the progression free survival (PFS) rate at 8 months and disease control rate (DCR). The secondary endpoints are overall survival (OS), tumor response rate (TRR), duration of response, evaluation of biomarkers: CD3 + , CD4 + and CD8 + T cell infiltration, as well as any change in the PD-L1 expression through percutaneous core biopsy when compared with the baseline biopsy following 1 cycle of Nivolumab and SBRT.
Discussion
SRBT alone showed promising results in the literature by both inducing the immune system locally and having abscopal effects on distant metastases. Moreover, given the prevalence of PD-L1 in solid tumors, targeting it or its receptor has become the mainstay of novel immunotherapeutic drugs use. A combination of both has never been explored in the scope of CCA and that is the aim of this study.
Trial registration
ClinicalTrials.gov
NCT04648319
, April 20, 2018.
Journal Article
The role of urine derived exosome metalloproteinases as biomarkers for prostate cancer detection may be confounded by non-malignant prostatic inflammation
Matrix metalloproteinases (MMPs) are emerging as promising diagnostic and prognostic biomarkers for prostate cancer (PCa). This study explored the association between urinary exosome MMP levels and the incidence of prostate cancer. Urine samples were collected from patients undergoing prostate biopsy or prostatectomy, and from age-matched healthy controls. A total of 147 patients participated, including 37 patients who provided samples before prostatectomy, 41 patients before a biopsy that turned out positive, 21 patients before a biopsy that turned out negative, and 48 healthy controls. The study found that MMP-2 expression was similar in patients with prostate cancer and healthy controls but significantly higher in those with a negative biopsy. MMP-9 expression was elevated in patients with a positive biopsy and even higher in those with a negative biopsy. Multivariate logistic regression, adjusted for age, showed that increased MMP-2 expression was linked to a higher likelihood of a negative biopsy result (OR 1.12 [1.002,1.252],
P
= 0.046), while increased MMP-9 expression was associated with a higher probability of prostate cancer diagnosis (OR 1.106 [1.002,1.22],
P
= 0.045). These findings suggest that urinary MMP-9 levels are elevated in PCa patients, though even higher levels in biopsy-negative cases may reflect confounding factors such as benign prostatic inflammation.
Journal Article
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
With five novel therapies shown to improve survival in metastatic castration-resistant prostate cancer (CRPC) in the last 3 years, patients are now living longer and experiencing better quality of life. Since docetaxel became standard of care for men with symptomatic metastatic CRPC, three artificial treatment “spaces” have emerged for prostate cancer drug development: pre-docetaxel, docetaxel combinations, and following docetaxel. Multiple therapies are currently under development in both early and late stage CRPC. Additionally, the novel agents abiraterone, radium-223, cabazitaxel, and enzalutamide have all been approved in the post-docetaxel setting. Strategies for patient selection and treatment sequencing are therefore urgently required. In this comprehensive review, we will summarize the preclinical and clinical data available with regards to sequencing of the novel treatments for CRPC.
Journal Article
The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study
Background
The role of young age (< 40 years) at diagnosis as an independent risk factor for adverse outcomes in female patients with breast cancer has been highlighted in several studies. In this prospective study, we assessed the difference in 10-year survival between two groups of patients diagnosed with non-metastatic breast cancer based on an age cutoff of 40 years. We also assessed the impact of factors including tumor characteristics, molecular markers and immunohistochemical markers on survival outcomes, highlighting the interaction of those variables with age.
Methods
A total of 119 female patients with newly diagnosed non-metastatic breast cancer were recruited at the American University of Beirut Medical Center (AUBMC) between July 2011 and May 2014. Patients were recruited and divided into 2 age groups (< 40 and ≥ 40 years). In addition to clinical characteristics, we assessed immunohistochemistry including estrogen, progesterone and HER2 receptors, p53, cyclin B1, vascular endothelial growth factor receptor (VEGFR), and ki-67. Germline BRCA mutations were also performed on peripheral blood samples. Patient and tumor characteristics were compared between the age groups. 10-year overall survival (OS) and disease-free survival (DFS) were estimated accordingly. Cox regression analysis was performed in order to assess the effect of the different variables on clinical outcomes.
Results
After a median Follow-up of 96 (13–122) months, the estimated 10-year OS was 98.6% for patients ≥40 as compared to 77.6% in patients < 40 (
p
= 0.001). A similar trend was found for 10-year DFS reaching 90% for patients ≥40 and 70.4% for those < 40 (
p
= 0.004). On multivariate analysis for DFS and OS, only younger age (< 40 years), higher stage and triple negative phenotype among other parameters assessed significantly affected the outcome in this cohort.
Conclusion
This prospective study confirms the association between younger age and adverse survival outcomes in patients with non-metastatic breast cancer. Future studies of the whole genome sequences may reveal the genomic basis underlying the clinical differences we have observed.
Journal Article
The economic burden of cancer care for Syrian refugees: a population-based modelling study
Cancer represents a substantial health burden for refugees and host countries. However, no reliable data on the costs of cancer care for refugees are available, which limits the planning of official development assistance in humanitarian settings. We aimed to model the direct costs of cancer care among Syrian refugee populations residing in Jordan, Lebanon, and Turkey.
In this population-based modelling study, direct cost per capita and per incident case for cancer care were estimated using generalised linear models, informed by a representative dataset of cancer costs drawn from 27 EU countries. A range of regression specifications were tested, in which cancer costs were modelled using different independent variables: gross domestic product (GDP) per capita, crude or age-standardised incidence, crude or age-standardised mortality, and total host country population size. Models were compared using the Akaike information criterion. Total cancer care costs for Syrian refugees in Jordan, Lebanon, and Turkey were calculated by multiplying the estimated direct cancer care costs (per capita) by the total number of Syrian refugees, or by multiplying the estimated direct cancer costs (per incident case [crude or age-standardised]) by the number of incident cancer cases in Syrian refugee populations. All costs are expressed in 2017 euros (€).
Total cancer care costs for all 4·74 million Syrian refugees in Jordan, Lebanon, and Turkey in 2017 were estimated to be €140·23 million using the cost per capita approach, €79·02 million using the age-standardised incidence approach, and €33·68 million using the crude incidence approach. Under the lowest estimation, and with GDP and total country population as model predictors, the financial burden of cancer care was highest for Turkey (€25·18 million), followed by Lebanon (€6·40 million), and then Jordan (€2·09 million).
Cancer among the Syrian refugee population represents a substantial financial burden for host countries and humanitarian agencies, such as the UN Refugee Agency. New ways to provide financial assistance need to be found and must be coupled with clear, prioritised pathways and models of care for refugees with cancer.
UK Research and Innovation Global Challenges Research Fund: Research for Health in Conflict-Middle East and North Africa region (R4HC-MENA).
Journal Article